MiMedx Group (MDXG) Guides FY16 Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
MiMedx Provides 2016 Guidance With Forecasted Revenue Growth In Excess Of 30% And Operating Earnings Growth Of 80% Or Greater
December 16, 2015 5:00 PM ESTMARIETTA, Ga., Dec. 16, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its outlook for 2016.
On December 15, 2015, the MiMedx Board of Directors approved the Company's 2016 Business Plan and related budget. Â To supplement its 2016 guidance, the Company is also reporting certain strategic and tactical detail associated with its 2016 Business Plan.
2016 Guidance Highlights
The... More
